Literature DB >> 18608105

Are statin medications safe in patients with ALS?

Lorne Zinman1, Reza Sadeghi, Marek Gawel, Dan Patton, Alex Kiss.   

Abstract

Statin medications for elevated cholesterol are one of the most commonly prescribed medications worldwide. The aim of this study was to determine if statin medications affect the rate of disease progression, the severity and frequency of muscle cramping, and serum CK levels in patients with ALS. We conducted a prospective cohort study in patients diagnosed with ALS with statin medication as the predetermined exposure variable and the rate of decline of the ALS Functional Rating Scale-Revised (ALSFRS-R) as the primary outcome. One hundred and sixty-four consecutive patients with laboratory supported probable, clinically probable, or clinically definite ALS were evaluated from January 2006 to September 2007. Thirty-two patients (20%) were taking statin medications and 132 were in the control group. After adjusting for covariates, we found a highly significant increase in the rate of decline in the ALSFRS-R for the statin group (1.71 units/month) compared to the control group (1.05 units/month, pB0.0001) representing a 63% increase in the rate of functional decline. Patients on statin therapy also reported a significant increase in muscle cramp frequency and severity (pB0.0001). This study has demonstrated a strong association between statin medications and an increased rate of functional decline and muscle cramping in patients with ALS. Although this association does not prove a causal relationship, it is prudent to exercise caution and discuss discontinuation or replacement of statin medications in patients with ALS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18608105     DOI: 10.1080/17482960802031092

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  20 in total

1.  Quinine-responsive muscle cramps in X-linked bulbospinal muscular atrophy Kennedy.

Authors:  J Finsterer; C Stöllberger
Journal:  J Neurol       Date:  2009-03-22       Impact factor: 4.849

2.  Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.

Authors:  Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

3.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

Review 4.  [Diagnostics and treatment of statin-associated muscle symptoms].

Authors:  Ursula Kassner; Stefanie Grunwald; Dominik Spira; Nikolaus Buchmann; Thomas Bobbert; Elisabetta Gazzerro; Tim Hollstein; Simone Spuler; Elisabeth Steinhagen-Thiessen
Journal:  Internist (Berl)       Date:  2021-06-18       Impact factor: 0.743

Review 5.  AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis.

Authors:  Nirma D Perera; Bradley J Turner
Journal:  Neurochem Res       Date:  2015-07-23       Impact factor: 3.996

6.  Atorvastatin Protects NSC-34 Motor Neurons Against Oxidative Stress by Activating PI3K, ERK and Free Radical Scavenging.

Authors:  Seok-Ho Lee; Na-Young Choi; Hyun-Jeung Yu; Jinse Park; Hojin Choi; Kyu-Yong Lee; Yong-Min Huh; Young Joo Lee; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2015-01-11       Impact factor: 5.590

7.  Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Authors:  Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

8.  Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.

Authors:  Xiaowei W Su; Wint Nandar; Elizabeth B Neely; Zachary Simmons; James R Connor
Journal:  Muscle Nerve       Date:  2016-05-19       Impact factor: 3.217

Review 9.  Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.

Authors:  Chafic Y Karam; Sabrina Paganoni; Nanette Joyce; Gregory T Carter; Richard Bedlack
Journal:  Am J Hosp Palliat Care       Date:  2014-09-08       Impact factor: 2.500

Review 10.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.